1. Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer
- Author
-
Pagan, E, Ruggeri, M, Bianco, N, Bucci, E, Graffeo, R, Borner, M, Giordano, M, Gianni, L, Rabaglio, M, Freschi, A, Cretella, E, Seles, E, Farolfi, A, Simoncini, E, Ciccarese, M, Rauch, D, Favaretto, A, Honecker, F, Berardi, R, Franzetti-Pellanda, A, Gelber, S, Partridge, A, Goldhirsch, A, Bagnardi, V, Pagani, O, Ribi, K, Pagan, Eleonora, Ruggeri, Monica, Bianco, Nadia, Bucci, Eraldo Oreste, Graffeo, Rossella, Borner, Markus, Giordano, Monica, Gianni, Lorenzo, Rabaglio, Manuela, Freschi, Andrea, Cretella, Elisabetta, Seles, Elena, Farolfi, Alberto, Simoncini, Edda, Ciccarese, Mariangela, Rauch, Daniel, Favaretto, Adolfo, Honecker, Friedemann, Berardi, Rossana, Franzetti-Pellanda, Alessandra, Gelber, Shari, Partridge, Ann H., Goldhirsch, Aron, Bagnardi, Vincenzo, Pagani, Olivia, Ribi, Karin, Pagan, E, Ruggeri, M, Bianco, N, Bucci, E, Graffeo, R, Borner, M, Giordano, M, Gianni, L, Rabaglio, M, Freschi, A, Cretella, E, Seles, E, Farolfi, A, Simoncini, E, Ciccarese, M, Rauch, D, Favaretto, A, Honecker, F, Berardi, R, Franzetti-Pellanda, A, Gelber, S, Partridge, A, Goldhirsch, A, Bagnardi, V, Pagani, O, Ribi, K, Pagan, Eleonora, Ruggeri, Monica, Bianco, Nadia, Bucci, Eraldo Oreste, Graffeo, Rossella, Borner, Markus, Giordano, Monica, Gianni, Lorenzo, Rabaglio, Manuela, Freschi, Andrea, Cretella, Elisabetta, Seles, Elena, Farolfi, Alberto, Simoncini, Edda, Ciccarese, Mariangela, Rauch, Daniel, Favaretto, Adolfo, Honecker, Friedemann, Berardi, Rossana, Franzetti-Pellanda, Alessandra, Gelber, Shari, Partridge, Ann H., Goldhirsch, Aron, Bagnardi, Vincenzo, Pagani, Olivia, and Ribi, Karin
- Abstract
Purpose: Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and described the 5-year trajectories of quality of life (QoL) and symptoms in young women (≤40 years) with hormone receptor-positive breast cancer (BC). Methods: We retrieved data on clinical characteristics and non-persistence from the medical annual records in the European cohort of the “Helping Ourselves, Helping Others: The Young Women's BC Study” (IBCSG 43-09 HOHO). Women completed surveys at baseline, biannually for three years, and annually for another seven years. Data collection included sociodemographic information, QoL aspects assessed by the Cancer Rehabilitation Evaluation System-Short Form and symptoms assessed by the Breast Cancer Prevention Trial symptom scales. Cox regression models were applied to identify factors associated with non-persistence. Results: The cumulative risk of interrupting ET within 5 years was 27.7 % (95 % CI, 21.5–35.2). The QoL subscale scores remained stable over 5 years, with slight improvements in the physical subscale. Hot flashes decreased (p < 0.001), while vaginal problems intensified (p < 0.001) over time. Being married without children and having difficulties interacting and communicating with the medical team were significantly associated with non-persistence. Conclusions: Discussing the desire to conceive with partnered childless women and establishing a good relationship with the medical team may be important in addressing the non-persistence in young BC survivors. As recent data suggests the safety of pausing ET to conceive, this approach may be a reasonable future option to limit non-persistence.
- Published
- 2024